行业动态 | 复宏汉霖创新PD-L1xVEGF双抗加速推进I期临床

药学进展
Dec 31, 2025

“点击蓝字 关注我们复宏汉霖创新PD-L1xVEGF双抗加速推进I期临床PPS2025年12月29日,复宏汉霖(2696.HK)宣布,公司自主研发的创新型重组人源化抗PD-L1与VEGF双特异性抗体HLX37在晚期/转移性实体瘤受试者中开展的首次人体临床试验(HLX37-FIH101)已于中国完成受试者给药。HLX37作用机制结合了两种治疗路径:1)阻断PD-1 /PD-L1结合:通过阻断肿瘤细胞...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10